| Autor: |
Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos |
| Rok vydání: |
2023 |
| Popis: |
Purpose:Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S. phase I results of taletrectinib.Patients and Methods:Patients ≥18 years old with neuroendocrine tumors, with tumor-induced pain, or tumors harboring ROS1/NTRK rearrangements were eligible. Accelerated titration followed by modified continuous reassessment method and escalation with overdose control was used (50–1,200 mg once daily or 400 mg twice daily). Primary objectives were safety/tolerability, and MTD determination. Secondary objectives were food-effect pharmacokinetics and antitumor activity.Results:A total of 46 patients were enrolled. Steady-state peak concentration (Cmax) and exposure (AUC0-8) increased dose dependently from 50-mg to 800-mg once-daily doses. The ratio of the geometric mean of AUC0-24 between low-fat-diet-fed/fasted state was 123% (90% confidence interval, 104%–149%). Dose-limiting toxicities (grade 3 transaminases increase) occurred in two patients (1,200-mg once-daily dose). MTD was 800 mg once daily. Most common treatment-related adverse events were nausea (47.8%), diarrhea (43.5%), and vomiting (32.6%). Pain score reductions were observed in the 800-mg once-daily dose cohort. Confirmed objective response rate was 33.3% among the six patients with RECIST-evaluable crizotinib-refractory ROS1+ NSCLC. One patient with TPM3-NTRK1 differentiated thyroid cancer achieving a confirmed partial response of 27 months at data cutoff. We identified a cabozantinib-sensitive ROS1 L2086F as an acquired taletrectinib-resistance mutation.Conclusions:Taletrectinib has manageable toxicities at the MTD of 800 mg daily. Preliminary efficacy was observed in patients with crizotinib-refractory ROS1+ NSCLC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
